Mga Batayang Estadistika
| CIK | 1840706 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SOPHiA GENETICS SA
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 15, 2025 |
SOPHiA GENETICS SA 200,000 Ordinary Shares FILED PURSUANT TO RULE 424(B)(3) REGISTRATION NO. 333-289270 PROSPECTUS SOPHiA GENETICS SA 200,000 Ordinary Shares Pursuant to this prospectus, the selling shareholder may offer ordinary shares from time to time if and to the extent as it may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than prevailing market prices or at pr |
|
| August 15, 2025 |
SOPHiA GENETICS SA Up to $50,000,000 Ordinary Shares FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333-289266 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED AUGUST 15, 2025) SOPHiA GENETICS SA Up to $50,000,000 Ordinary Shares We have entered into a sales agreement with TD Securities (USA) LLC (the “sales agent”), dated August 5, 2025, relating to the sale of our ordinary shares, par value CHF 0.05 per share, offered by this prospectus supplement an |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive of |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5. 2025. As filed with the Securities and Exchange Commission on August 5. 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R. |
|
| August 5, 2025 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| August 5, 2025 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| August 5, 2025 |
SOPHIA GENETICS SA ORDINARY SHARES SALES AGREEMENT Exhibit 1.2 SOPHIA GENETICS SA ORDINARY SHARES SALES AGREEMENT August 5, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: Section 1. Offering an |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025. As filed with the Securities and Exchange Commission on August 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R. |
|
| August 5, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables F-3 SOPHiA GENETICS SA Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Ordinary Shares 457(o) Debt Debt Securities 457(o) Other Warrants 457(o) Other Subscription Rights 457(o) Other Purchase Contracts 457(o) Other Units 457(o) Fees to be Paid 1 Unallocated (Universal) Shelf 457(o) $ 0. |
|
| August 5, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 SOPHiA GENETICS SA Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares (1) Other 200,000 $ 3. |
|
| August 5, 2025 |
SOPHiA GENETICS Reports Second Quarter 2025 Results Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2025 Results BOSTON, United States and ROLLE, Switzerland, August 5, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results •Revenue was $18.3 million, up 16% year-over-year •Gross |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
Exhibit 107 FILING FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) SOPHiA GENETICS SA (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Ordinary shares, par value CHF 0. |
|
| June 18, 2025 |
Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA 2 / 38 Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, siège, but et durée de la Société Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a corporation with its registered office in Rolle, Canton of Vaud, governed by these articles of association (the Articles of Association) and the Swiss Code of Obligations (CO). |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offi |
|
| May 16, 2025 |
Democratizing Data-Driven Medicine, Together ESG Impact Summary Since our inception, sustainability has been a cornerstone of our mission at SOPHiA GENETICS. |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offic |
|
| May 8, 2025 |
www.investorvote.com/SOPH Step 1: Go to www.investorvote.com/SOPH. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/SOPH or scan the QR code — login details are located in the shaded bar below. SOPHiA GENETICS SA Shareholder Annual General Meeting No |
|
| May 8, 2025 |
To the shareholders of SOPHiA GENETICS SA (Nasdaq SOPH) (the Company) Invitation to the Annual General Meeting Date and Time: Wednesday, June 18, 2025, at 8:00 a. |
|
| May 8, 2025 |
1. 2. 3. 4. 6b. 6c. 7. 8. 5a. 5b 5c. 5d. 9a. 9b. 9c. 10a. 5e. 5f. 5g. 6a. 10b. 1 U P X For Against Abstain For Against Abstain For Against Abstain For Against Abstain Proposals — The Board of Directors recommend a vote FOR Proposals 1 – 10.A 045GFG If a new proposal is made under a new or existing agenda item, I instruct the independent proxy to: Vote in accordance with the recommendation of the B |
|
| May 8, 2025 |
1. 2. 3. 4. 6b. 6c. 7. 8. 5a. 5b 5c. 5d. 9a. 9b. 9c. 10a. 5e. 5f. 5g. 6a. 10b. 1 U P X For Against Abstain For Against Abstain For Against Abstain For Against Abstain Proposals — The Board of Directors recommend a vote FOR Proposals 1 – 10.A 045GEG If a new proposal is made under a new or existing agenda item, I instruct the independent proxy to: Vote in accordance with the recommendation of the B |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offic |
|
| May 6, 2025 |
SOPHiA GENETICS Reports First Quarter 2025 Results Exhibit 99.3 SOPHiA GENETICS Reports First Quarter 2025 Results BOSTON, United States and ROLLE, Switzerland, May 6, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results •Revenue was $17.8 million, up 13% year-over-year or 15% on a |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offic |
|
| May 6, 2025 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| May 6, 2025 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive off |
|
| March 4, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| March 4, 2025 |
SOPHiA GENETICS STANDARD OPERATING PROCEDURE 10b5-1 Plan policy SOPHiA GENETICS STANDARD OPERATING PROCEDURE 10b5-1 Plan policy 1.PURPOSE A 10b5-1 plan that meets the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934 (such plan, a “Trading Plan”) enables Eligible Persons as defined in 2. AUDIENCE below to buy or sell a predetermined number of shares in SOPHiA GENETICS SA, a public company incorporated, organized and existing under the laws |
|
| March 4, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, George Cardoza, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| March 4, 2025 |
SOPHiA GENETICS Policy Against Insider Trading SOPHiA GENETICS POLICY Policy Against Insider Trading 1.PURPOSE & SCOPE SOPHiA GENETICS SA and its subsidiaries (collectively, the “Company”) will, without exception, comply with all applicable laws and regulations in conducting its business. Each employee and each director is expected to abide by this policy against insider trading (the “Policy”). When carrying out Company business, employees and |
|
| March 4, 2025 |
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results BOSTON, United States and ROLLE, Switzerland, March 4, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. |
|
| March 4, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jurgi Camblong, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| March 4, 2025 |
SUPPLY AGREEMENT This SUPPLY AGREEMENT (the "Agreement") is dated and effective December 6th, 2021 (the "Effective Date"), by and between Watchmaker Genomics, Inc. |
|
| March 4, 2025 |
aoapostincreasejuly2024p Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, siège, but et durée de la Société Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a corporation with its registered office in Rolle, Canton of Vaud, governed by these articles of association (the Articles of Association) and the Swiss Code of Obligations (CO). |
|
| March 4, 2025 |
SOPHiA GENETICS 2024 Annual Report TABLE OF CONTENTS SOPHiA GENETICS 2024 Annual Report TABLE OF CONTENTS 1 Business Update 6 Financial Review 53 Corporate Governance 77 Report of the Statutory Auditor on the Consolidated Financial Statements for the Year Ended December 31, 2024 91 Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2024 98 Report of the Statutory Auditor on the Statutory Financial Statements of S |
|
| March 4, 2025 |
Mergers and similar arrangements DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to 79,321,220 ordinary shares, each with a par value of CHF 0. |
|
| March 4, 2025 |
End Customer Fund Project Id # Supplemental Terms. The parties agree that the following new sections are added to and amend the Agreement. All terms used but not defined in these sections will have the same meaning provided in the Agreement. The parties agree these Supplemental Terms only apply to the signing entity, except as otherwise stated in the Agreement. Azure Credit Customer will receive a one-time Azure Credit (“Credit |
|
| March 4, 2025 |
Contrat de bail pour locaux commerciaux Contrat de bail pour locaux commerciaux entre Swisscanto Anlagestiftung, Zürich p. |
|
| March 4, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| March 4, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2024) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| November 13, 2024 |
SOPH / SOPHiA GENETICS SA / GENERATION INVESTMENT MANAGEMENT LLP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive |
|
| November 5, 2024 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| November 5, 2024 |
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer (“CFO”) and Chief Operating Officer (“COO”), has been promoted to company President, effective November 5, 2024. |
|
| November 5, 2024 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive |
|
| November 5, 2024 |
Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2024 Results Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Qu |
|
| August 6, 2024 |
Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2024 Results Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss BOSTON, United States and ROLLE, Switzerland, August 6, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 3 |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive of |
|
| August 6, 2024 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| August 6, 2024 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| July 22, 2024 |
Ent fAs filed with the Securities and Exchange Commission on July 22, 2024. Ent fAs filed with the Securities and Exchange Commission on July 22, 2024. Registration No. 333-280060 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorpo |
|
| July 22, 2024 |
July 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 1, 2024 |
As filed with the Securities and Exchange Commission on July 1 , 2024. As filed with the Securities and Exchange Commission on July 1 , 2024. Registration No. 333-280060 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporatio |
|
| June 25, 2024 |
Exhibit 99.1 Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, siège, but et durée de la Société Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a c |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle / VD Switzerland (Address of principal executive |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle / VD Switzerland (Address of principal executive |
|
| June 24, 2024 |
Exhibit 99.1 SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting Shareholders adopt all proposals at Annual General Meeting Boston, US and Rolle, Switzerland, June 24, 2024 – SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the “AGM”) was held at the Company’ |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offi |
|
| June 7, 2024 |
Exhibit 99.1 Democratizing Data - Driven Medicine, Together ESG impact summary We have also included relevant points from the SASB Industry - Specific Materiality Map within this summary to further illustrate specific metrics and results we have achieved at this stage in our company. As we continue our ESG journey, this summary marks our commitment to transparently manage and inform its audience o |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) SOPHiA GENETICS SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary Shares Rule 457(c) 200,000(1) $5. |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024. As filed with the Securities and Exchange Commission on June 7, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offic |
|
| May 15, 2024 |
Exhibit 99.4 1 U P X For Against Abstain Abstain Against F or Abstain Against For Abstain Against For 4. 3. 2. 1. 5d. 5c. 5 b . 5a. 6a. 5g. 5 f . 5e. 8. 7. 6c. 6b. 9d. 9c. 9 b . 9a. 10 b . 10a. Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. + + Proposals — The Board of Directors recommend a vote FOR Proposals 1 – 10. A q |
|
| May 15, 2024 |
Exhibit 99.2 Online Go to www.investorvote.com/SOPH or scan the QR code — login details are located in the shaded bar below. 04 0 3OB + + 2 N O T www.investorvote.com/SOPH Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you wa |
|
| May 15, 2024 |
Exhibit 99.1 To the shareholders of SOPHiA GENETICS SA (Nasdaq SOPH) (the Company) Invitation to the Annual General Meeting Date and Time: Monday, June 24, 2024, at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST Location: Offices of SOPHiA GENETICS SA, La Pièce 12, 1180 Rolle/VD, Switzerland (AGM 2024) 1 Dear Fellow Shareholders, 2023 was a tremendous year for SOPHiA GENETICS. We continued buildin |
|
| May 15, 2024 |
Exhibit 99.3 1 U P X For Against Abstain Abstain Against F or Abstain Against For Abstain Against For 4. 3. 2. 1. 5d. 5c. 5 b . 5a. 6a. 5g. 5 f . 5e. 8. 7. 6c. 6b. 9d. 9c. 9 b . 9a. 10 b . 10a. Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 04 0 3NB + + Proposals — The Board of Directors recommend a vote FOR Proposals 1 |
|
| May 7, 2024 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| May 7, 2024 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| May 7, 2024 |
Exhibit 99.3 SOPHiA GENETICS Reports First Quarter 2024 Results Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed BOSTON, United States and ROLLE, Switzerland, May 7, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2 |
|
| May 7, 2024 |
Execution Version Credit Agreement and Guaranty dated as of May 2, 2024 among SOPHiA GENETICS SA as Borrower, The Guarantors From Time To Time Party Hereto, as Guarantors, The Lenders From Time To Time Party Hereto, as Lenders, and Perceptive Credit Holdings IV, LP, as the Administrative Agent and as a Lender 4894-2985-1820 7040231 #98195096v26 Table of Contents Section Heading Page Schedules: Schedule 1 — Commitments and Warrant Shares Schedule 2 — Notice Addresses Schedule 3 — Products Schedule 7. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive offic |
|
| May 7, 2024 |
Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH TRANSACTION IS EFFECTIVE UNDER THE SECURITIES ACT AND SUCH TRANSACTION IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) SUCH TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW. |
|
| March 5, 2024 |
Compensation Report 2023 SOPHiA GENETICS SA Compensation Report 2023 of SOPHiA GENETICS SA SOPHiA GENETICS SA Rolle Report of the statutory auditor to the General Meeting on the compensation report 2023 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Rolle Report on the audit of the compensation report Opinion We have audited the compensation report of SOPHiA GENETICS SA (the Company) for the year ended 31 December 2023. |
|
| March 5, 2024 |
SOPHiA GENETICS Clawback policy SOPHiA GENETICS POLICY Clawback policy 1.Purpose & scope This Clawback policy (this “Policy”) sets forth the policy on recovery by SOPHiA GENETICS SA (“SOPH”) and its subsidiaries (collectively, the “SG Group”) of erroneously awarded incentive-based compensation received by one or more of the following persons in the event of an accounting restatement due to SOPH’s material non-compliance with any |
|
| March 5, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jurgi Camblong, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| March 5, 2024 |
Mergers and similar arrangements DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to 76,898,164 ordinary shares, all of which 65,230,559 were outstanding, each with a par value of CHF 0. |
|
| March 5, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. |
|
| March 5, 2024 |
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 BOSTON, United States and ROLLE, Switzerland, March 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. |
|
| March 5, 2024 |
Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 SOPHiA GENETICS SA Rolle Report of the statutory auditor to the General Meeting on the financial statements 2023 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Rolle Report on the audit of the financial statements Opinion We have audited the financial statements of SOPHiA GENETICS SA (the Company), which comprise the balance sheet as at 31 December 2023, and the statement of loss for the year then ended, and notes to the financial statements, including a summary of significant accounting policies. |
|
| March 5, 2024 |
Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 SOPHiA GENETICS SA Rolle Report of the statutory auditor to the General Meeting on the consolidated financial statements 2023 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Rolle Report on the audit of the consolidated financial statements Opinion We have audited the consolida |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2023) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| March 5, 2024 |
Dear Fellow Shareholders, 2023 was a tremendous year for SOPHiA GENETICS. We continued building the future of data-driven medicine, and in doing so, creating long-term value for our customers and our shareholders. In many ways, 2023 was the year of AI. It was the first time that the general public gained access to powerful AI models and learned what they can do. As the Co-founder and leader of an |
|
| March 5, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| March 5, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ross Muken, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| March 5, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| February 20, 2024 |
SOPH / SOPHiA GENETICS SA / Balderton Capital VI, S.L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SOPHIA GENETICS SA (Name of Issuer) Ordinary Shares, CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2024 |
SOPH / SOPHiA GENETICS SA / GENERATION INVESTMENT MANAGEMENT LLP Passive Investment SC 13G/A 1 generation-soph123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 13, 2024 |
SOPH / SOPHiA GENETICS SA / Balderton Capital VI, S.L.P. - SC 13G/A Passive Investment SC 13G/A 1 d770065dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SOPHIA GENETICS SA (Name of Issuer) Ordinary Shares, CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the app |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive o |
|
| January 10, 2024 |
Exhibit 99.1 SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today Boston, MA and Rolle, Switzerland, January 10, 202 |
|
| January 10, 2024 |
Exhibit 99.2 J.P. Morgan Healthcare Conference January 2024 Jurgi Camblong CEO and Co - Founder at SOPHiA GENETICS Cautionary notices 2 This presentation contains statements that constitute forward - looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, bus |
|
| November 7, 2023 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive |
|
| November 7, 2023 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| November 7, 2023 |
Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023 Record results on growth acceleration, significant improvement in operating loss and cash burn BOSTON, United States and ROLLE, Switzerland, November 7, 2023 — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the th |
|
| October 18, 2023 |
Exhibit 99.1 SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting edge science BOSTON and ROLLE, Switzerland, October 18, 2023– SOPHiA GENETICS (Nasdaq: SOPH), a ca |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive o |
|
| August 14, 2023 |
Exhibit 99.1 Democratizing Data - Driven Medicine Ross Muken Chief Financial Officer & Chief Operating Officer August 15, 2023 Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial po |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive of |
|
| August 8, 2023 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| August 8, 2023 |
Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023 Robust growth and efficient expense execution continues BOSTON, United States and ROLLE, Switzerland, August 8, 2023 — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2023. Recent |
|
| August 8, 2023 |
SOPHiA GENETICS SA Up to $50,000,000 Ordinary Shares FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333-266704 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED AUGUST 15, 2022) SOPHiA GENETICS SA Up to $50,000,000 Ordinary Shares We have entered into a sales agreement with Cowen and Company, LLC (the “sales agent”), dated August 8, 2023, relating to the sale of our ordinary shares, par value CHF 0.05 per share, offered by this prospectus supplement and |
|
| August 8, 2023 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 1180 Rolle Switzerland (Address of principal executive offic |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive of |
|
| August 8, 2023 |
SOPHiA GENETICS SA SALES AGREEMENT Exhibit 1.1 SOPHiA GENETICS SA SALES AGREEMENT August 8, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: Section 1. Offering and Sale of Shares. The Comp |
|
| June 27, 2023 |
Exhibit 99.1 Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, siège, but et durée de la Société Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a c |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| June 26, 2023 |
Exhibit 99.1 SOPHiA GENETICS Publishes Results of 2023 Annual General Meeting BOSTON and Rolle, Switzerland, June 26, 2023 – SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, is pleased to announce that its Annual General Shareholders Meeting (the “AGM“) was held at the Company’s new headquarters, La Piece 12, 1180 Roll |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| June 6, 2023 |
Exhibit 99.1 Democratizing Data - Driven Medicine Dr. Jurgi CAMBLONG Chief Executive Officer & Co - Founder June 6, 2023 Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position |
|
| May 31, 2023 |
Exhibit 99.1 SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors Microsoft’s Deputy Chief Technology Officer to be appointed at Annual Shareholders’ Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Treti |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal e |
|
| May 18, 2023 |
SOPH / SOPHiA Genetics SA / Schindel Yair Chaim - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares, par value CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) aMoon Growth Fund Limited Partnership aMoon Growth Fund G.P. Limited Partnership aMoon General Partner Ltd. aMoon Ed |
|
| May 17, 2023 |
Exhibit 99.3 For Against Abstain 1. 4b. 4f. 2. 4c. 4g. For Against Abstain 3. 4d. 4h. For Against Abstain 4a. 4e. 5a. For Against Abstain 5b. 5c. 6. 7. 8a. 8b. 8c. 9a. 9b. 9c. 9d. 9e. 9f. 9g. Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03TSEB + + Proposals — The Board of Directors recommend a A vote FOR Proposals 1 – |
|
| May 17, 2023 |
Exhibit 99.4 1 U P X 1. 4b. 4f. For Against Abstain 2. 4c. 4g. For Against Abstain 3. 4d. 4h. For Against Abstain 4a. 4e. 5a. For Against Abstain 5b. 5c. 6. 7. 8a. 8b. 8c. 9a. 9b. 9c. 9d. 9e. 9f. 9g. Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. 03TSDB + + Proposals — The Board of Directors recommend a A vote FOR Propos |
|
| May 17, 2023 |
May 17, 2023 Re: SOPHiA GENETICS SA Form 20-F for the Fiscal Year Ended December 31, 2022 Form 6-K furnished May 9, 2023 File No. |
|
| May 17, 2023 |
Exhibit 99.2 000004 C 1234567890 ENDORSEMENTLINE SACKPACK MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 1234 5678 9012 345 www.investorvote.com/SOPH Step 1: Go to www.investorvote.com/SOPH Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.invest |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal e |
|
| May 17, 2023 |
To the shareholders of SOPHiA GENETICS SA (the Company) Invitation to the Annual General Meeting Exhibit 99.1 To the shareholders of SOPHiA GENETICS SA (the Company) Invitation to the Annual General Meeting Date and Time: Monday, June 26, 2023, at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST Location: Offices of SOPHiA GENETICS SA, La Pièce 12, 1180 Rolle, Switzerland 1 Dear Fellow Shareholders, 2022 was an incredible year for SOPHiA GENETICS. We made tremendous progress across our strategi |
|
| May 12, 2023 |
EX-99.1 2 dp193725ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Building a Data - Driven World Dr. Jurgi CAMBLONG Chief Executive Officer & Co - Founder May 12, 2023 Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal e |
|
| May 9, 2023 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 –Unaudited Interim Condensed Consolidated Statements of Loss F-3 –Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 –Unaudited Interim Condensed Consolidated Balance Sheets F-5 –Unaudited Interim Condensed Consolidated Statements of |
|
| May 9, 2023 |
Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| May 9, 2023 |
Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023 Strong growth momentum and efficient expense execution continues BOSTON, United States and LAUSANNE, Switzerland, May 9, 2023 — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the first quarter ended March 31, 2023. Recent High |
|
| May 9, 2023 |
6-K 1 q12023sophiageneticssa6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sul |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principa |
|
| March 14, 2023 |
Exhibit 99.1 SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis Collaboration provides a solution for a more in-depth analysis of cancer biomarkers BOSTON and LAUSANNE, Switzerland, March 14, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comp |
|
| March 7, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| March 7, 2023 |
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results Fourth Quarter Revenue Growth Accelerates; Operating Losses Notably Moderate BOSTON and LAUSANNE, Switzerland, March 7, 2023 — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022. |
|
| March 7, 2023 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to 66,398,164 ordinary shares, all of which 64,231,220 were outstanding, each with a par value of CHF 0. |
|
| March 7, 2023 |
Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 EX-99.3 4 iasfinancialstatements.htm EX-99.3 Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2022 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidat |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2022) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| March 7, 2023 |
Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 EX-99.5 6 switzerlandstatutoryfinanc.htm EX-99.5 Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the financial statements 2022 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the financial statements O |
|
| March 7, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ross Muken, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mate |
|
| March 7, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (th |
|
| March 7, 2023 |
Dear Fellow Shareholders, 2022 was an incredible year for SOPHiA GENETICS. We made tremendous progress across our strategic objectives and demonstrated a continued ability to execute our vision. I am extraordinarily proud of what we have achieved and am excited by the opportunities ahead. We have come a long way since 2011, from just a handful of people in a 10 square meter room with a vision to d |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| March 7, 2023 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jurgi Camblong, certify that: 1.I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| March 7, 2023 |
Consent of PricewaterhouseCoopers SA CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. |
|
| March 7, 2023 |
Compensation Report 2022 SOPHiA GENETICS SA Compensation Report 2022 of SOPHiA GENETICS SA SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the compensation report 2022 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the compensation report Opinion We have audited the compensation report of SOPHiA GENETICS SA (the Company) for the year ended 31 December 2022. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princi |
|
| February 13, 2023 |
SOPH / SOPHiA GENETICS SA / GENERATION INVESTMENT MANAGEMENT LLP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
Exhibit 99.1 SOPHiA GENETICS Expands Partnership with AstraZeneca to include Multimodal Approaches for Cancer Drug Development The expanded partnership aims to leverage the global SOPHiA DDM™ platform and multimodal algorithmic capabilities to lead a new era of precision oncology by improving early patient identification and diagnosis, optimizing clinical development, and accelerating adoption of |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princip |
|
| January 10, 2023 |
EX-99.1 2 dp186784ex9901.htm EXHIBIT 99.1 #JPM CONF2023 J P M C O N F 2023 Building a data - driven world Dr. Jurgi Camblong Chief Executive Officer & Co - Founder Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future r |
|
| January 10, 2023 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Schedule 13D (the “Schedule 13D”), filed by the undersigned with respect to Ordinary Shares, par value CHF 0.05 per share, of SOPHiA GENETICS SA is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| January 10, 2023 |
SOPH / SOPHiA GENETICS SA / Schindel Yair Chaim - SC 13D Activist Investment SC 13D 1 zk2328998.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares, par value CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) aMoon Growth Fund Limited Partnership aMoon Growth Fund G.P. Limited Partnership aMoon General Partner Lt |
|
| November 8, 2022 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 ?Unaudited Interim Condensed Consolidated Statements of Loss F-3 ?Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 ?Unaudited Interim Condensed Consolidated Balance Sheets F-5 ?Unaudited Interim Condensed Consolidated Statements of |
|
| November 8, 2022 |
6-K 1 q32022sophiageneticssa6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Sain |
|
| November 8, 2022 |
Exhibit 99.2 Management?s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| November 8, 2022 |
EX-99.3 4 sophiageneticssaex993q32022.htm EX-99.3 Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2022 Sustainable growth momentum evident despite foreign exchange headwinds BOSTON, United States and LAUSANNE, Switzerland, November 8, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial re |
|
| November 1, 2022 |
Exhibit 99.1 SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDMTM health data analysis platform available with Microsoft Azure Geneva, Switzerland – November 1, 2022 - SOPHiA GENETICSTM (Nasdaq: SOPH), a cloud-native software company in the healthcare space, is embarking on a mul |
|
| November 1, 2022 |
6-K 1 dp1835636k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| September 20, 2022 |
6-K 1 dp1807706k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| September 20, 2022 |
#S OP H iNVES T O RD A Y #S OP H iNVES T O RD A Y Exhibit 99.1 #S OP H iNVES T O RD A Y #S OP H iNVES T O RD A Y Welcome Jennifer Pottage, Head of Investor Relations Opening remarks Troy Cox, Chairman of the Board Building a data - driven world Dr. Jurgi Camblong, Chief Executive Officer Growing the SOPHiA network Ken Freedman, Chief Revenue Officer Capitalizing on our expanding biopharma opportunity Peter Casasanto, Chief BioPharma Officer 15 - |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princ |
|
| August 11, 2022 |
CORRESP 1 filename1.htm August 11, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz Re: SOPHiA GENETICS SA Registration Statement on Form F-3 Registration No. 333-266704 Dear Ms. Nimitz: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the e |
|
| August 9, 2022 |
Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022 Steady Operational Performance Amidst Macroeconomic Headwinds BOSTON, United States and LAUSANNE, Switzerland, August 9, 2022 ? SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30, 2022. Recent Hig |
|
| August 9, 2022 |
Exhibit 4.2 SOPHiA GENETICS SA INDENTURE Dated as of [] [], as Trustee TABLE OF CONTENTS Article 1 Definition and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 Article 2 The Securities Section 2.01. Issuable in Series 5 Section 2.02. Establishment of Te |
|
| August 9, 2022 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 ?Unaudited Interim Condensed Consolidated Statements of Loss F-3 ?Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 ?Unaudited Interim Condensed Consolidated Balance Sheets F-5 ?Unaudited Interim Condensed Consolidated Statements of |
|
| August 9, 2022 |
6-K 1 q22022sophiageneticssa6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint- |
|
| August 9, 2022 |
Exhibit 99.2 Management?s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| August 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) SOPHiA GENETICS SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carr |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 9. 2022. F-3 1 dp178404f3.htm FORM F-3 As filed with the Securities and Exchange Commission on August 9. 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of incorp |
|
| June 15, 2022 |
6-K 1 dp1753266k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Swit |
|
| June 15, 2022 |
SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary Exhibit 99.1 SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 ? SOPHiA GENETICS SA (Nasdaq: SOPH) (?the Company?), today announced that the Company has published its first Environmental, Social and Governance Impact Summary (?ESG Impact Summary?). The ESG Impact Summary highlights the Company?s policies, on |
|
| June 15, 2022 |
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting EX-99.2 3 dp175326ex9902.htm EXHIBIT 99.2 Exhibit 99.2 SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting BOSTON, United States and LAUSANNE, Switzerland, June 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH) (“the Company”), is pleased to announce the Annual General Meeting (“the Meeting”) was held at the Company’s headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earli |
|
| June 15, 2022 |
EX-99.2 3 dp175286ex9902.htm EXHIBIT 99.2 Exhibit 99.2 ESG Impact Summary June 2022 The information contained in this document is accurate only as of its date. In addition, this document contains statements that constitute forward - looking statements, which are subject to risks and uncertainties, including those described in our filings with the U.S. Securities and Exchange Commission. We disclai |
|
| June 15, 2022 |
Articles of Association of SOPHiA GENETICS SA de SOPHiA GENETICS SA Exhibit 99.1 Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, si?ge, but et dur?e de la Soci?t? Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a c |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| June 14, 2022 |
6-K 1 dp1752146k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Swi |
|
| June 14, 2022 |
SOPHiA GENETICS Achieves CE-IVD Certification using its SOPHiA DDM™ Platform Exhibit 99.1 SOPHiA GENETICS Achieves CE-IVD Certification using its SOPHiA DDM? Platform BOSTON, United States and LAUSANNE, Switzerland ? June 14, 2022 ? SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM? Platform, a |
|
| May 16, 2022 |
Exhibit 99.2 |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal e |
|
| May 16, 2022 |
To the shareholders of SOPHiA GENETICS SA Invitation to the Annual General Meeting EX-99.1 2 dp173094ex9901.htm EXHIBIT 99.1 Exhibit 99.1 To the shareholders of SOPHiA GENETICS SA Invitation to the Annual General Meeting Date and Time: Wednesday, June 15, 2022 at 8:00 a.m. EDT / 2:00 p.m. CEST Location: Headquarters of SOPHiA GENETICS SA, Rue du Centre 172, 1025 St-Sulpice VD, Switzerland (no physical shareholder attendance) 1/14 Dear Fellow Shareholders, 2021 was a tremendous a |
|
| May 10, 2022 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 ?Unaudited Interim Condensed Consolidated Statements of Loss F-3 ?Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss F-4 ?Unaudited Interim Condensed Consolidated Balance Sheets F-5 ?Unaudited Interim Condensed Consolidated Statements of |
|
| May 10, 2022 |
EX-99.3 4 sophiageneticssaex9931.htm EX-99.3 Exhibit 99.3 SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022 Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first |
|
| May 10, 2022 |
Exhibit 99.2 Management?s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our interim condensed consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is inc |
|
| May 10, 2022 |
6-K 1 sophiageneticssa6-k1.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| May 5, 2022 |
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors Exhibit 99.1 SOPHiA GENETICS Announces Nomination of Jean-Michel Coss?ry to Board of Directors BOSTON, United States and LAUSANNE, Switzerland ? May 5, 2022 ? SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Coss?ry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Coss?ry as a member of the Board of |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principal |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principa |
|
| April 26, 2022 |
SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform Exhibit 99.1 SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM? Platform BOSTON, United States and LAUSANNE, Switzerland ? April 26, 2022 ? SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM? Platform, securing its position as one of the largest knowledge shar |
|
| March 15, 2022 |
Consent of PricewaterhouseCoopers SA Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-258121 and No. 333-258122) of SOPHiA GENETICS SA of our report dated March 15, 2022 relating to the consolidated financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers SA Lausanne, Switzerland March |
|
| March 15, 2022 |
6-K 1 soph-6k20220315.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Swi |
|
| March 15, 2022 |
Supply Agreement between SOPHiA GENETICS SA and New England Biolabs, Inc., dated January 4, 2019 Exhibit 4.11 Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA(SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. SUPPLY AGREEMENT This Supply Agreement (this ?Agreement?) is made as of the 4th day of January, 2019 (the ?Ef |
|
| March 15, 2022 |
Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA?s annual report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Ac |
|
| March 15, 2022 |
Exhibit 12.2 Certification Pursuant to Rules 13a-14(a) And 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ross Muken, certify that: 1. I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma |
|
| March 15, 2022 |
Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2021 Exhibit 99.5 Statutory Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2021 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the financial statements 2021 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the financial statements Opinion We have audited the financial |
|
| March 15, 2022 |
EX-99.1 2 soph-ex99155.htm EX-99.1 Exhibit 99.1 SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 2021 2022 Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, March 15, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the fourth |
|
| March 15, 2022 |
Exhibit 13.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 The certification set forth below is being submitted in connection with SOPHiA GENETICS SA?s annual report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Ac |
|
| March 15, 2022 |
EX-2.1 2 soph-ex217.htm EX-2.1 Exhibit 2.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Changes in Our Share Capital During the Last Three Fiscal Years As of December 31, 2021, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to 63,857,604 ordin |
|
| March 15, 2022 |
Exhibit 12.1 Certification Pursuant to Rules 13a-14(a) And 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jurgi Camblong, certify that: 1. I have reviewed this annual report on Form 20-F of SOPHiA GENETICS SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| March 15, 2022 |
EX-99.3 4 soph-ex99358.htm EX-99.3 Exhibit 99.3 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2021 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of S |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2022 |
Exhibit 4.10 Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETIC SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. MASTER ALLIANCE AGREEMENT This Master Alliance Agreement (“Agreement”) is entered into by GE Precision Health |
|
| March 15, 2022 |
Compensation Report 2021 SOPHiA GENETICS SA EX-99.4 5 soph-ex9946.htm EX-99.4 Exhibit 99.4 Compensation Report 2021 of SOPHiA GENETICS SA SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the compensation report 2021 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice We have audited the accompanying compensation report of SOPHiA GENETICS SA for the year ended 3 |
|
| March 15, 2022 |
EX-99.2 3 soph-ex992175.htm EX-99.2 Dear Fellow Shareholders, 2021 was a tremendous and unforgettable year for SOPHiA GENETICS, as we made meaningful strides across our strategic objectives during our first fiscal year as a publicly traded company. I am immensely proud of our progress, which we believe directly reflects our continued ability to execute our vision, and I am thoroughly excited by th |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of principa |
|
| March 14, 2022 |
EX-99.1 2 dp169062ex9901.htm EXHIBIT 99.1 Exhibit 99.1 SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON & ALISO VIEJO, Calif., United States and LAUSANNE, Switzerland |
|
| March 9, 2022 |
SOPHiA GENETICS HRD Solution Adopted in Asia Pacific EX-99.1 2 dp168898ex9901.htm EXHIBIT 99.1 EXHIBIT 99.1 SOPHiA GENETICS HRD Solution Adopted in Asia Pacific BOSTON, Mass, United States, LAUSANNE, Switzerland, and TAIPEI CITY, Taiwan – March 9, 2022 – SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first ins |
|
| March 9, 2022 |
6-K 1 dp1688986k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Sw |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princ |
|
| February 22, 2022 |
First Japanese Institution to Utilize SOPHiA GENETICS’ Myeloid Plus Solution EX-99.1 2 dp167478ex9901.htm EXHIBIT 99.1 Exhibit 99.1 First Japanese Institution to Utilize SOPHiA GENETICS’ Myeloid Plus Solution BOSTON, United States, LAUSANNE, Switzerland, and HIROSHIMA, Japan – February 22, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular pro |
|
| February 15, 2022 |
AGREEMENT OF REPORTING PERSONS EXHIBIT 99.1 AGREEMENT OF REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each |
|
| February 15, 2022 |
SOPH / SOPHiA GENETICS SA / GENERATION INVESTMENT MANAGEMENT LLP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 14, 2022 |
SOPH / SOPHiA GENETICS SA / Coucke Marc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares, par value CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
SOPH / SOPHiA GENETICS SA / Balderton Capital VI, S.L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOPHIA GENETICS SA (Name of Issuer) Ordinary Shares, CHF 0.05 per share (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2022 |
EX-99.1 2 d281631dex991.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge th |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princi |
|
| January 26, 2022 |
SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer Exhibit 99.1 SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer BOSTON and LAUSANNE, Switzerland, January 26, 2022 ? SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a background in serving some of the most innova |
|
| January 11, 2022 |
6-K 1 dp1650036k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| January 11, 2022 |
EX-99.1 2 dp165003ex9901.htm EXHIBIT 99.1 Exhibit 99.1 SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer |
|
| January 10, 2022 |
Exhibit 99.1 Democratizing Data - Driven Medicine Together Dr. Jurgi Camblong, Co - Founder & CEO J.P. Morgan Healthcare Conference - January 11, 2022 This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financi |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princip |
|
| January 10, 2022 |
Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business EX-99.1 2 dp164951ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business BOSTON and LAUSANNE, Switzerland, January 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto |
|
| January 10, 2022 |
6-K 1 dp1649516k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| January 6, 2022 |
AGREEMENT OF REPORTING PERSONS EX-99.1 2 g44783922b.htm JOINT FILING AGREEMENT EXHIBIT 99.1 AGREEMENT OF REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing ag |
|
| January 6, 2022 |
SOPH / SOPHiA GENETICS SA / GENERATION INVESTMENT MANAGEMENT LLP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOPHiA GENETICS SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) H82027105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princi |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princi |
|
| November 29, 2021 |
Exhibit 99.1 SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021 Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma companies CHICAGO, Novemb |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland (Address of princ |
|
| November 10, 2021 |
EX-99.3 4 dp161420ex9903.htm EXHIBIT 99.3 Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2021 Financial Results and Raises 2021 Guidance Third quarter year-over-year revenue growth of 45%; executed Master Alliance Agreement with GE Healthcare BOSTON and LAUSANNE, Switzerland, November 10, 2021 — SOPHiA GENETICS SA (Nasdaq: SOPH), today reported financial results for the third quarter ended Sep |
|
| November 10, 2021 |
6-K 1 dp1614206k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| November 10, 2021 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 - Unaudited Interim Condensed Consolidated Statement of Loss F-3 - Unaudited Interim Condensed Consolidated Statement of Comprehensive Loss F-4 - Unaudited Interim Condensed Consolidated Balance Sheet F-5 - Unaudited Interim Condensed Consolidated Statement of |
|
| November 10, 2021 |
EX-99.2 3 dp161420ex9902.htm EXHIBIT 99.2 Exhibit 99.2 Management’s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discus |
|
| November 4, 2021 |
EX-99.1 2 dp160837ex9901.htm EXHIBIT 99.1 Exhibit 99.1 SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8 New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, November 1, 2021 — SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances d |
|
| November 4, 2021 |
6-K 1 dp1608376k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| October 12, 2021 |
EX-99.1 2 dp159716ex9901.htm EXHIBIT 99.1 Exhibit 99.1 SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases SOPHiA Clinical Exome Solution v3 offers a streamlined end-to-end workflow to facilitate the assessment of challenging Mendelian disorders BOSTON and LAUSANNE, Switzerland, October 12, 2021 — SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a globa |
|
| October 12, 2021 |
6-K 1 dp1597166k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| September 9, 2021 |
SOPHiA GENETICS SA Unaudited Interim Condensed Consolidated Financial Statements EX-99.1 2 dp157574ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents Unaudited Interim Condensed Consolidated Financial Statements F-2 - Unaudited Interim Condensed Consolidated Statement of Loss F-3 - Unaudited Interim Condensed Consolidated Statement of Comprehensive Loss F-4 - Unaudited Interim Condensed Consolidated Balance Sheet F-5 - Unaudited I |
|
| September 9, 2021 |
Exhibit 99.2 Management?s discussion and analysis of financial conditions and results of operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is included as Exhibit 9 |
|
| September 9, 2021 |
6-K 1 dp1575746k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice |
|
| September 9, 2021 |
SOPHiA GENETICS Reports Second Quarter 2021 Financial Results and Issues 2021 Guidance EX-99.3 4 dp157574ex9903.htm EXHIBIT 99.3 Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2021 Financial Results and Issues 2021 Guidance BOSTON and LAUSANNE, Switzerland, Sept 9, 2021 — SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021. Recent Highlights · Revenue was $10.2 million for the second quarter, representing a 72% increase o |
|
| August 25, 2021 |
Articles of Association of SOPHiA GENETICS SA de SOPHiA GENETICS SA EX-99.1 2 dp156736ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, siège, but et durée de la Société Article 1 Article 1 Name, registered office Under the name S |
|
| August 25, 2021 |
6-K 1 dp1567366k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Sw |
|
| August 24, 2021 |
EX-99.1 2 dp156641ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America Highly accurate HRD detection offers affordable and easily implementable solutions, opening new doors for healthcare São Paulo, Brazil and Boston, MA – August 24, 2021 - Dasa, the largest integrated healthcare network |
|
| August 24, 2021 |
6-K 1 dp1566416k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Sw |
|
| July 27, 2021 |
6-K 1 dp1550896k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021. Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Rue du Centre 172 CH-1025 Saint-Sulpice Swit |
|
| July 27, 2021 |
Articles of Association of SOPHiA GENETICS SA de SOPHiA GENETICS SA Exhibit 99.1 Articles of Association of SOPHiA GENETICS SA Statuts de SOPHiA GENETICS SA Articles of Association of SOPHiA GENETICS SA / Statuts de SOPHiA GENETICS SA Section 1 Name, registered office, purpose and duration of the Company Section 1 Raison sociale, si?ge, but et dur?e de la Soci?t? Article 1 Article 1 Name, registered office Under the name SOPHiA GENETICS SA (the Company) exists a c |
|
| July 23, 2021 |
Our SOPHiA Platform within the Healthcare Ecosystem 424B4 1 d101766d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257646 Prospectus 13,000,000 Shares SOPHiA GENETICS SA Ordinary Shares This is an initial public offering of ordinary shares by SOPHiA GENETICS SA. We are offering 13,000,000 ordinary shares. The initial public offering price is $18.00 per ordinary share. Prior to this offering, there has been n |
|
| July 23, 2021 |
As filed with the Securities and Exchange Commission on July 23, 2021 As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. |
|
| July 23, 2021 |
As filed with the Securities and Exchange Commission on July 23, 2021 As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. |
